CN INT DEV CORP (00264) subsidiary purchases molds
Zhonglian Development Holdings (00264) issued an announcement that the buyer (an indirectly non-wholly-owned subsidiary of the Company) entered into a purchase agreement with the seller on April 15, 2025, to acquire Mold Group One for a total consideration of RMB 1.6999 million (equivalent to approximately HKD 1.8869 million).
CN INT DEV CORP (00264) announced that the buyer (an indirect non-wholly owned subsidiary of the company) entered into a purchase agreement with the seller on April 15, 2025, to purchase Mold Group 1 for a total consideration of RMB 1.6999 million (equivalent to approximately HKD 1.8869 million).
On November 12, 2025, the buyer entered into a second purchase agreement with the seller (amended and supplemented by Supplementary Agreement 1 dated April 24, 2026), to purchase Mold Group 2 for a total consideration of RMB 1.8657 million (equivalent to approximately HKD 2.0709 million); and on December 3, 2025, the buyer entered into a third purchase agreement with seller 2 (amended and supplemented by Supplementary Agreement 2 dated April 24, 2026) to purchase Mold Group 3 for a total consideration of RMB 2.3552 million (equivalent to approximately HKD 2.6143 million).
In order to enhance the market competitiveness of the group, the group aims to purchase molds from Chinese manufacturers in order to optimize the production process and effectively stabilize the cost fluctuations related to mold procurement. In addition, by solving the logistics redundancies and delivery cycle restrictions when purchasing from overseas suppliers in France, the group can establish a more flexible and resilient cost-effective management framework for its manufacturing operations. The directors believe that these purchase agreements and their underlying transaction terms are fair and reasonable, and are in the overall interest of the company and its shareholders.
Related Articles

CT VISION (00994): Yang Sen appointed as independent non-executive director

PW MEDTECH (01358) spent 1.356 million Hong Kong dollars to repurchase 1.149 million shares on May 8th.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) saw a 40% increase in sales of weight-loss drugs in April after prices were reduced in India.
CT VISION (00994): Yang Sen appointed as independent non-executive director

PW MEDTECH (01358) spent 1.356 million Hong Kong dollars to repurchase 1.149 million shares on May 8th.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) saw a 40% increase in sales of weight-loss drugs in April after prices were reduced in India.






